Anzeige
Mehr »
Donnerstag, 07.08.2025 - Börsentäglich über 12.000 News
Große CEO-Enthüllung: Analysten sehen +56% Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A140ML | ISIN: JE00BYSS4X48 | Ticker-Symbol: 038
Tradegate
07.08.25 | 09:32
9,842 Euro
+0,76 % +0,074
1-Jahres-Chart
NOVOCURE LIMITED Chart 1 Jahr
5-Tage-Chart
NOVOCURE LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
9,77410,05515:21
9,77410,05515:03

Aktuelle News zur NOVOCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.07.Why NovoCure Stock Is Cratering Today7
24.07.Novocure: Steady Ahead of Key Milestones20
24.07.Novocure Reports Second Quarter 2025 Financial Results555Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual...
► Artikel lesen
NOVOCURE Aktie jetzt für 0€ handeln
24.07.NovoCure Ltd - 10-Q, Quarterly Report2
24.07.NovoCure Ltd - 8-K, Current Report3
23.07.NovoCure Earnings Preview2
23.07.NovoCure Q2 2025 Earnings Preview4
08.07.NovoCure stock initiated with Buy rating at Ladenburg Thalmann4
08.07.Ladenburg Thalmann startet NovoCure-Aktie mit Kaufempfehlung9
03.07.NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data3
30.06.Novocure to Report Second Quarter 2025 Financial Results231Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast...
► Artikel lesen
27.06.Demystifying NovoCure: Insights From 4 Analyst Reviews4
06.06.NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial5
02.06.Novocure study shows improved pancreatic cancer survival9
02.06.NovoCure's Tumor Treating Fields Boosts One-Year And Pain-Free Survival In Pancreatic Cancer Trial3
02.06.H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data5
02.06.NovoCure Ltd - 8-K, Current Report1
01.06.Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)'s TTFields Therapy Succeeds in Phase 3 Trial5
31.05.Zai Lab Limited: Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting850TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for...
► Artikel lesen
31.05.Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting500TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients...
► Artikel lesen
Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1